DNA AND RNA STUDIES INTO THE NPM-ALK REARRANGEMENT IN KI-1 POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA, DIAGNOSTIC APPLICATIONS

Бібліографічні деталі
Автори:	Waggott, W, Lo, Y, Bastard, C, Gatter, K, Leroux, D, Mason, D, Boultwood, J, Wainscoat, J
Формат:	Journal article
Опубліковано:	1994

Detection of NPM-ALK DNA rearrangement in CD30 positive anaplastic large cell lymphoma.
за авторством: Waggott, W, та інші
Опубліковано: (1995)

NPM-ALK gene fusion and Hodgkin's disease.
за авторством: Waggott, W, та інші
Опубліковано: (1997)

NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
за авторством: Vijay Kumar Singh, та інші
Опубліковано: (2019-09-01)

Identification of NPM-ALK-interacting proteins involved in the transformation of anaplastic lymphomas
за авторством: Voena, C, та інші
Опубліковано: (2005)

The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
за авторством: Voena, C, та інші
Опубліковано: (2007)

ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
за авторством: Federica Lovisa, та інші
Опубліковано: (2015-01-01)

Anaplastic Lymphoma Kinase (ALK) Rearrangement of Lung Adenocarcinoma among North Sumatera Population
за авторством: Muhammad Yusuf Adira Putra, та інші
Опубліковано: (2025-01-01)

Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.
за авторством: Antoine Buetti-Dinh, та інші
Опубліковано: (2016-01-01)

The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein
за авторством: Pearson Joel D, та інші
Опубліковано: (2012-06-01)

Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene
за авторством: Jo-Anne van der Krogt, та інші
Опубліковано: (2017-09-01)

The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity
за авторством: Paolo Bonvini, та інші
Опубліковано: (2009-07-01)

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK+ T‐cell lymphoma
за авторством: Wenyu Shi, та інші
Опубліковано: (2017-09-01)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
за авторством: Bhawana George, та інші
Опубліковано: (2019-07-01)

Case report: anaplastic lymphoma kinase (ALK) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumab
за авторством: Naoko Shigeta, та інші
Опубліковано: (2023-04-01)

ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions
за авторством: Katrien Van Roosbroeck, та інші
Опубліковано: (2010-03-01)

Educational Case: ALK-Negative Anaplastic Large Cell Lymphoma
за авторством: Akira Satou MD, PhD, та інші
Опубліковано: (2020-01-01)

Pathobiology of ALK-negative anaplastic large cell lymphoma
за авторством: Stefano A. Pileri, та інші
Опубліковано: (2011-06-01)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK+ T-cell lymphoma
за авторством: Bhawana George, та інші
Опубліковано: (2023-06-01)

Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma.
за авторством: Pulford, K, та інші
Опубліковано: (2000)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
за авторством: Yuan Wang, та інші
Опубліковано: (2022-02-01)

MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
за авторством: E. V. Chernyshova, та інші
Опубліковано: (2017-01-01)

Anaplastic large cell Ki-1 lymphoma arising in bone.
за авторством: Edwards, MS, та інші
Опубліковано: (1993)

ALK signaling and target therapy in anaplastic large cell lymphoma
за авторством: Fabrizio eTabbo, та інші
Опубліковано: (2012-05-01)

Small cell pattern of ALK‐negative anaplastic large cell lymphoma with double‐hit rearrangements of DUSP22 and TP63
за авторством: Yui Niiyama‐Uchibori, та інші
Опубліковано: (2024-08-01)

Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant
за авторством: Vishwanath Sathyanarayanan, та інші
Опубліковано: (2014-11-01)

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
за авторством: Christian Britschgi, та інші
Опубліковано: (2020-08-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
за авторством: Muhammad Wasi Alam, та інші
Опубліковано: (2019-07-01)

A Case of ALK-Positive Anaplastic Large Cell Lymphoma of the Male Breast
за авторством: Wang X, та інші
Опубліковано: (2023-11-01)

Quantification of minimal disseminated disease by quantitative polymerase chain reaction and digital polymerase chain reaction for NPM-ALK as a prognostic factor in children with anaplastic large cell lymphoma
за авторством: Christine Damm-Welk, та інші
Опубліковано: (2020-08-01)

<i>DUSP22</i> rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma
за авторством: Lianqun Qiu, та інші
Опубліковано: (2022-12-01)

Acquired L1196M ALK mutation in anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma during alectinib administration
за авторством: Kazuhiro Noguchi, та інші
Опубліковано: (2023-02-01)

<i>DUSP22</i>-rearranged ALK-negative anaplastic large cell lymphoma is a pathogenetically distinct disease but can have variable clinical outcome
за авторством: Kerry J. Savage, та інші
Опубліковано: (2022-12-01)

ALK-Positive Anaplastic Large Cell Lymphoma: A Diagnostic Dilemma for the Otolaryngologist in a Resource Poor Setting
за авторством: Nicholas Figaro, та інші
Опубліковано: (2021-01-01)

Granulomatous Inflammation in a Patient with ALK-Negative Anaplastic Large Cell Lymphoma
за авторством: Özlem Kandemir Alibakan, та інші
Опубліковано: (2022-02-01)

Regulation of CD45 phosphatase by oncogenic ALK in anaplastic large cell lymphoma
за авторством: Giulia Mura, та інші
Опубліковано: (2023-01-01)

Therapeutic Targeting of the Anaplastic Lymphoma Kinase (ALK) in Neuroblastoma—A Comprehensive Update
за авторством: Annette K. Brenner, та інші
Опубліковано: (2021-09-01)

Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK‐positive anaplastic large‐cell lymphoma refractory to chemotherapy and brentuximab vedotin
за авторством: Ritsuko Nakai, та інші
Опубліковано: (2019-12-01)

NIPA (Nuclear Interaction Partner of ALK) Is Crucial for Effective NPM-ALK Mediated Lymphomagenesis
за авторством: Stefanie Kreutmair, та інші
Опубліковано: (2022-05-01)

Pulmonary Spindle Cell Carcinoma Presenting Anaplastic Lymphoma Kinase Rearrangement
за авторством: Kei Sonehara, та інші
Опубліковано: (2023-09-01)

DNA AND RNA STUDIES INTO THE NPM-ALK REARRANGEMENT IN KI-1 POSITIVE ANAPLASTIC LARGE-CELL LYMPHOMA, DIAGNOSTIC APPLICATIONS

Схожі ресурси

Схожі ресурси